Cephalon Still a Stressor

You have to wonder if Cephalon (CEPH Quote) might act more shareholder-friendly by mailing motion-sickness medication to investors.

In recent years, Cephalon has produced a stream of upside surprises and downside shocks -- financial, regulatory, research-related -- which jolt the stock and keep stockholders queasy. Just in the past 15 months, shares bounced from the mid-$50s to the high $70s, then slipped to the mid-$60s, then rose to low $80s, then dropped to the high $60s.

Now, they're in the low $70s as Cephalon prepares to release third-quarter earnings on Nov. 8. ...